OSE Immunotherapeutics and AbbVie Partner on Novel Anti-Inflammatory Program in $713M Deal
OSE Immunotherapeutics has secured a major strategic partnership with pharmaceutical giant AbbVie for the development of its novel preclinical program OSE-230, aimed at treating chronic inflammation. The collaboration, announced as part of the company's recent business updates, carries a potential total value of $713 million.
Under the terms of the agreement, OSE Immunotherapeutics will receive an upfront payment of $48 million, with the remainder tied to development, regulatory, and commercial milestones. This partnership marks a significant advancement for OSE's innovative anti-inflammatory pipeline.
Strategic Growth Through Partnerships
The AbbVie collaboration is one of three major pharmaceutical agreements OSE has secured in recent months, demonstrating the company's growing prominence in the immunotherapy space. Notably, the company has also expanded its existing partnership with Boehringer Ingelheim, focusing on first-in-class SIRP𝛼 compounds.
The Boehringer Ingelheim collaboration, which initially centered on immuno-oncology applications, has now broadened to include cardiovascular indications, highlighting the versatility of OSE's therapeutic platforms.
Expanding Therapeutic Portfolio
OSE Immunotherapeutics continues to strengthen its position in the immunotherapy landscape through multiple development programs. The company's pipeline includes:
- Lusvertikimab, an anti-IL-7R monoclonal antibody showing promising results in ulcerative colitis
- Tedopi®, a proprietary cancer vaccine in Phase 3 trials for non-small cell lung cancer
- Various early-stage programs utilizing novel technologies, including mRNA therapeutics for inflammatory and autoimmune disorders
Corporate Development
To support its expanding operations, OSE has recently bolstered its leadership team with strategic appointments, including Dr. Sonya Montgomery as Chief Development Officer and Fiona Olivier as Chief Corporate Affairs and Investor Relations Officer. These appointments reflect the company's commitment to advancing its diverse therapeutic pipeline and strengthening its market position.
The series of successful partnerships and pipeline developments has contributed to strong financial performance, with the company reporting total income of €82.5 million for H1 2024, primarily driven by partnership revenues.